Vaxart Beheer

Beheer criteriumcontroles 3/4

De CEO Vaxart is Steven Lo, benoemd in Mar2024, heeft een ambtstermijn van 2.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.81M, bestaande uit 23.1% salaris en 76.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.23% van de aandelen van het bedrijf, ter waarde $ 361.31K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 4.8 jaar.

Belangrijke informatie

Steven Lo

Algemeen directeur

US$2.8m

Totale compensatie

Percentage CEO-salaris	23.13%
Dienstverband CEO	2.2yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Nieuw narratief • May 15

BARDA Reliance And Funding Risks Will Shape Oral Vaccine Prospects Longer Term

Catalysts About Vaxart Vaxart is a clinical stage biotechnology company developing oral pill vaccines for infectious diseases such as COVID 19 and norovirus. What are the underlying business or industry changes driving this perspective?

Analyseartikel • Jun 20

Vaxart, Inc. (NASDAQ:VXRT) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Vaxart, Inc. ( NASDAQ:VXRT ) shareholders would be excited to see that the share price has had a great month, posting a...

Analyseartikel • Feb 25

Lacklustre Performance Is Driving Vaxart, Inc.'s (NASDAQ:VXRT) 36% Price Drop

Vaxart, Inc. ( NASDAQ:VXRT ) shareholders won't be pleased to see that the share price has had a very rough month...

Analyseartikel • Jan 04

Revenues Not Telling The Story For Vaxart, Inc. (NASDAQ:VXRT) After Shares Rise 47%

Vaxart, Inc. ( NASDAQ:VXRT ) shareholders would be excited to see that the share price has had a great month, posting a...

Analyseartikel • Nov 16

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

The Vaxart, Inc. ( NASDAQ:VXRT ) share price has fared very poorly over the last month, falling by a substantial 29...

Analyseartikel • Aug 20

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Vaxart, Inc. ( NASDAQ:VXRT ) shares have had a really impressive month, gaining 39% after a shaky period beforehand...

Analyseartikel • Jun 15

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Key Insights The projected fair value for Vaxart is US$0.77 based on 2 Stage Free Cash Flow to Equity Current share...

Analyseartikel • Nov 08

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyseartikel • Jun 30

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyse CEO-vergoeding

Hoe is Steven Lo's beloning veranderd ten opzichte van Vaxart's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2026	n/a	n/a	US$37m
Dec 31 2025	US$3m	US$650k	US$16m
Sep 30 2025	n/a	n/a	-US$51m
Jun 30 2025	n/a	n/a	-US$57m
Mar 31 2025	n/a	n/a	-US$58m
Dec 31 2024	US$2m	US$474k	-US$67m

Compensatie versus markt: De totale vergoeding ($USD 2.81M ) Steven } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.66M ).

Compensatie versus inkomsten: De vergoeding van Steven is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Steven Lo (58 yo)

2.2yrs

Tenure

US$2,810,419

Compensatie

Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. From October 2019 to August 2022, Mr. Lo was the President, Chief Executive Officer and member of the board of direct...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Steven Lo	President	2.2yrs	US$2.81m	0.23% $ 361.3k
Sean Tucker	Senior VP & Chief Scientific Officer	16.3yrs	US$1.14m	0.15% $ 239.4k
James Cummings	Chief Medical Officer	4.8yrs	US$1.25m	0.15% $ 236.4k
Jeroen Grasman	CFO, Principal Accounting Officer & Principal Financial Officer	1yr	geen gegevens	0.23% $ 351.8k
Edward Berg	Senior VP & General Counsel	4.3yrs	geen gegevens	0.11% $ 173.0k
Laurie Hastings	Senior Vice President of Human Resources	1.3yrs	geen gegevens	geen gegevens
Rajesh Kapoor	Senior Vice President of Quality	5.3yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VXRT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Steven Lo	President	2.2yrs	US$2.81m	0.23% $ 361.3k
Harry Greenberg	Member of Scientific & Clinical Advisory Board	4.8yrs	geen gegevens	geen gegevens
Elaine Heron	Independent Director	3.8yrs	US$141.52k	0.033% $ 52.0k
Stanley Plotkin	Member of Scientific & Clinical Advisory Board	4.8yrs	geen gegevens	geen gegevens
Stefan Gravenstein	Member of Scientific & Clinical Advisory Board	4.8yrs	geen gegevens	geen gegevens
George R. Siber	Member of Scientific & Clinical Advisory Board	4.8yrs	geen gegevens	geen gegevens
David Wheadon	Independent Director	5.1yrs	US$152.97k	0.013% $ 19.8k
Robert Belshe	Member of Scientific & Clinical Advisory Board	4.8yrs	geen gegevens	geen gegevens
William Watson	Lead Independent Director	3.8yrs	US$143.95k	0.045% $ 69.7k
Marion Pepper	Member of Scientific & Clinical Advisory Board	4.8yrs	geen gegevens	geen gegevens
Ralph Baric	Member of Scientific & Clinical Advisory Board	4.8yrs	geen gegevens	geen gegevens
Gregory Gray	Member of Scientific & Clinical Advisory Board	4.8yrs	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

76yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VXRT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/05/26 09:28
Aandelenkoers aan het einde van de dag	2026/05/26 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Vaxart, Inc. wordt gevolgd door 5 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Mayank Mamtani	B. Riley Securities, Inc.
Roger Song	Jefferies LLC
null null	Oppenheimer & Co. Inc.

Vaxart Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Vaxart, Inc., Annual General Meeting, Jul 16, 2026

Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

Vaxart, Inc. Announces Retirement of Michael J. Finney from the Board of Directors and Science and Technology Committee, Effective September 30, 2025

Vaxart, Inc., Annual General Meeting, May 21, 2025

Vaxart, Inc. Announces Board and Committee Changes

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Recent updates

Vaxart, Inc., Annual General Meeting, Jul 16, 2026

BARDA Reliance And Funding Risks Will Shape Oral Vaccine Prospects Longer Term

Vaxart, Inc. to Report Q1, 2026 Results on May 07, 2026

Vaxart, Inc. Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

Vaxart, Inc. announced that it expects to receive $25 million in funding from Lincoln Park Capital, LLC

Vaxart, Inc. Publishes Positive Data for Its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

Vaxart, Inc. to Report Q3, 2025 Results on Nov 13, 2025

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Vaxart Receives a Letter from the Office of the General Counsel of Nasdaq

Richard John Burgess Responds to Vaxart’s Governance Announcements

Vaxart, Inc. Reports Additional Phase 1 Data Supporting the Potential Efficacy of Its Second-Generation Norovirus Oral Vaccine Candidate

Richard John Burgess Files an Exempt Solicitation Statement with Vaxart

Vaxart, Inc. Announces Retirement of Michael J. Finney from the Board of Directors and Science and Technology Committee, Effective September 30, 2025

Richard John Burgess Urges Vaxart’s Shareholders to Vote Against Reverse Stock Split

Richard John Burgess Oppose Vaxart’s Latest Reverse Stock Split

Vaxart, Inc. to Report Q2, 2025 Results on Aug 13, 2025

Vaxart, Inc.(NasdaqCM:VXRT) dropped from S&P Global BMI Index

Vaxart, Inc.(NasdaqCM:VXRT) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Vaxart Common Stock, Suspends Trading Effective July 08

Vaxart, Inc. (NASDAQ:VXRT) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Vaxart, Inc. Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

New major risk - Financial position

Vaxart, Inc. Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

New major risk - Share price stability

Consensus revenue estimates increase by 171%

First quarter 2025 earnings released: US$0.068 loss per share (vs US$0.14 loss in 1Q 2024)

Vaxart, Inc. Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2B Covid-19 Trial

New major risk - Revenue and earnings growth

Price target increased by 24% to US$6.00

Vaxart, Inc. to Report Q1, 2025 Results on May 13, 2025

Vaxart, Inc., Annual General Meeting, May 21, 2025

New minor risk - Market cap size

Consensus revenue estimates decrease by 77%, EPS upgraded

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

No longer forecast to breakeven

Vaxart, Inc. to Report Fiscal Year 2024 Results on Mar 20, 2025

Vaxart, Inc. Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Lacklustre Performance Is Driving Vaxart, Inc.'s (NASDAQ:VXRT) 36% Price Drop

Vaxart, Inc. Enters into Modification No. 5 (The “Modification”) to the ATI-RRPV Project Award Agreement

Vaxart, Inc. Announces Board and Committee Changes

New major risk - Shareholder dilution

Vaxart Highlights Progress of Covid-19, Norovirus and Influenza Programs

Vaxart Announces Favorable Dsmb Review of Sentinel Cohort from Covid-19 Phase 2B Clinical Trial

Revenues Not Telling The Story For Vaxart, Inc. (NASDAQ:VXRT) After Shares Rise 47%

Vaxart, Inc. Provides Nasdaq Bid Price Non-Compliance Update

New minor risk - Share price stability

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

New major risk - Financial position

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Consensus revenue estimates increase by 113%, EPS downgraded

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Consensus revenue estimates increase by 865%

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Price target increased by 11% to US$5.25

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Now 27% overvalued after recent price rise

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes